PT  - JOURNAL ARTICLE
AU  - Stern, Dalia
AU  - de la Garza, Eduardo Arias
AU  - García-Romero, María Teresa
AU  - Lajous, Martin
TI  - COVID-19 mortality in children and young people in Mexico
AID  - 10.1101/2021.09.01.21262981
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.01.21262981
4099  - http://medrxiv.org/content/early/2021/09/05/2021.09.01.21262981.short
4100  - http://medrxiv.org/content/early/2021/09/05/2021.09.01.21262981.full
AB  - Objective To estimate COVID-19 and pre-pandemic low respiratory infection (LRI) mortality in children and young people in Mexico.Material and methods We estimated the percentage of total mortality attributable to COVID-19 (95% confidence intervals; 95%CI) and corresponding estimates for pre-pandemic LRI mortality.Results In 2019, LRIs represented 8.6% (95%CI 8.3, 8.9) of deaths in children 0-9 years and 2.0% (95%CI 1.8, 2.3) in those aged 10-19 years. In 2020, corresponding estimates for COVID-19 were 4.4% (95%CI 4.1, 4.6) and 3.7% (95%CI 3.4, 4.1).Conclusions Relative to LRI, COVID-19 may be exerting considerable mortality burden, particularly in older children and adolescents.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used publicly available dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicly available